Stockhub

ALTEOGEN Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

18 August 2022

  • curprev 00:4700:47, 18 August 2022 >Paris 1,053 bytes +1,053 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targ..."
Retrieved from "https://stockhub.co/research/ALTEOGEN_Inc."